ABSTRACT Background: Many randomized controlled trials (RCTs) and observational studies have provided information on the association between vitamin B-12 intake and biomarkers. The use of these data to estimate dose-response relations provides a useful means to summarize the body of evidence. Objective: We systematically reviewed studies that investigated vitamin B-12 intake and biomarkers of vitamin B-12 status and estimated dose-response relations with the use of a meta-analysis. Design: This systematic review included all RCTs, prospective cohort studies, nested case-control studies, and cross-sectional studies in healthy adult populations published through January 2010 that supplied or measured dietary vitamin B-12 intake and measured vitamin B-12 status as serum or plasma vitamin B-12, methylmalonic acid (MMA), or holotranscobalamin. We calculated an intake-status regression coefficient À b Á for each individual study and calculated the overall pooled b and SE À b Á by using random-effects meta-analysis on a double-log scale. Results: The meta-analysis of observational studies showed a weaker slope of dose-response relations than the meta-analysis of RCTs. The pooled dose-response relation of all studies between vitamin B-12 intake and status indicated that a doubling of the vitamin B-12 intake increased vitamin B-12 concentrations by 11% (95% CI: 9.4%, 12.5%). This increase was larger for studies in elderly persons (13%) than in studies in adults (8%). The dose-response relation between vitamin B-12 intake and MMA concentrations indicated a decrease in MMA of 7% (95% CI: 210%, 24%) for every doubling of the vitamin B-12 intake. The assessment of risk of bias within individual studies and across studies indicated risk that was unlikely to seriously alter these results. Conclusion: The obtained dose-response estimate between vitamin B-12 intake and status provides complementary evidence to underpin recommendations for a vitamin B-12 intake of populations.
INTRODUCTION
Severe and persistent deficiency of vitamin B-12 (cobalamin) in blood is associated with neurologic complications and hematologic abnormalities (1) (2) (3) . Moreover, the potential association between vitamin B-12 status in blood and several other health problems, such as cognitive decline (2, 4) , cardiovascular disease (5) , and osteoporosis (6, 7) , is an active area of scientific investigation. To be able to include the evidence on vitamin B-12 status in blood and health outcomes in the process of developing vitamin B-12 recommendations, it is essential to know the daily vitamin B-12 intake necessary to achieve normal or optimal values of vitamin B-12 status in blood.
Several studies investigated concentrations of vitamin B-12-related biomarkers in adults with different daily vitamin B-12 intakes (8) (9) (10) . In addition, a systematic review and metaanalysis of randomized controlled trials (RCTs) was performed to assess the effectiveness of biomarkers of vitamin B-12 status in reflecting changes in vitamin B-12 intake (1). However, metaanalytic methods have not yet been used to model vitamin B-12 status as a function of vitamin B-12 intakes. Such intake-status modeling enables the comparison and integration of results from RCTs with those from observational studies, thus incorporating a broader spectrum of population characteristics and a broader range of vitamin B-12 intake doses and forms. In addition, when the predictive value of the vitamin B-12 biomarker data on specific health outcomes is available, a curve that models the vitamin B-12 status as a function of intake is very informative to determine the daily vitamin B-12 intake dose necessary to achieve normal or optimal levels of vitamin B-12 status.
The aim of this article was to systematically review RCTs as well as observational studies that investigated vitamin B-12 intake and biomarkers of vitamin B-12 status and combine these studies in meta-analyses to model vitamin B-12 concentrations in serum or plasma as a function of vitamin B-12 intake.
SUBJECTS AND METHODS
The research was conducted within the framework of the European Micronutrient Recommendations Aligned Network of Excellence that aims to identify the vitamin B-12 requirements for the optimal health of adults and elderly people in general European populations. For the current article, we selected, from the overall search, the studies that reported on vitamin B-12 intake and vitamin B-12-related biomarkers. The review protocol can be requested from the corresponding author. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed in the reporting of this systematic review and meta-analyses.
Search strategy
We searched for all RCTs, prospective cohort studies, nested case-control studies, and cross-sectional studies in healthy human populations that supplied vitamin B-12 orally (RCTs) or measured dietary vitamin B-12 intake by using a validated food-frequency questionnaire, a dietary history method, a 24-h recall method for $3 d, or a food record or diary for $3 d (observational studies). In addition, we included only studies that measured vitamin B-12 status as serum or plasma vitamin B-12, serum or plasma methylmalonic acid (MMA), or serum or plasma holotranscobalamin and reported sufficient data or had sufficient data obtainable from the authors to estimate b and SE À b Á for the assumed linear relation on the log e -log e scale.
Studies were excluded if they were non-RCTs, retrospective cohort studies, nonnested case-control studies, were performed in infants, children, pregnant or lactating women or patients, or were commentaries, reviews, or duplicate publications from the same study.
Searches were performed of literature published through January 2009 by using MEDLINE (http://www.nlm.nih.gov/bds/ pmresources/html), Embase (http://www.embase.com), and the Cochrane library (http://www.thecochranelibrary.com) by using search terms on study designs in humans AND vitamin B-12 AND (intake OR status). See Tables 1-4 under "Supplemental data" in the online issue for details on search terms used for all databases. Moreover, we reviewed reference lists of literature reviews to search for additional relevant studies. An update of the search was performed of literature published through January 2010 by using the same libraries. Authors were contacted to request missing data or clarify methods or results.
Selection of articles
Of 5913 identified articles, 5005 articles were excluded on the basis of a review of the title and abstract (Figure 1 ). Full texts of the remaining 908 articles were assessed, 10% in duplicate by 2 investigators, to determine inclusion and exclusion. We excluded 824 studies because they did not meet the inclusion criteria. Of the remaining 84 studies, 35 studies were excluded because they did not investigate the relation between vitamin B-12 intake and vitamin B-12-related biomarkers but related either intake or status directly to a health endpoint. Thus, 49 studies remained for the purpose of this article.
Data extraction
For each of the identified manuscripts, data were extracted by one investigator, and 10% of this work was performed in duplicate by another investigator. For RCTs, extracted data included population characteristics, dose of vitamin B-12 in intervention and placebo supplements, duration of the study, dietary intake of vitamin B-12, mean concentration of vitamin B-12, MMA, and holotranscobalamin in plasma or serum at the end of the intervention period, or the change in concentration with a measure of variability. For observational studies, extracted data included population characteristics; mean vitamin B-12 intake and assessment method; concentration of vitamin B-12, MMA, and holotranscobalamin in plasma or serum; association and type of association (Spearman's rank correlation coefficient, Pearson's correlation coefficient, and linear regression coefficient) between vitamin B-12 intake and vitamin B-12-related biomarkers; and information on any transformations applied to obtain the reported associations. We converted the reported serum or plasma vitamin B-12 concentrations of all papers to picomoles per liter, where applicable, by using the following equation:
Data synthesis for RCTs
One article reported on 2 separate placebo-controlled trials (11), which were treated as 2 independent estimates in the analysis. If a study included 2 vitamin B-12-treated groups and one common control group (12) (13) (14) (15) , we treated the study as 2 independent estimates in the analysis and included the control group twice. If a study included 2 vitamin B-12-treated groups and 2 controls groups (16) or if results were only reported for men and women separately (15, 17) , we treated the study as 2 independent estimates in the analysis.
If postsupplementation concentrations were presented as the change from baseline (13, 16, (18) (19) (20) (21) , we calculated the mean final vitamin B-12 status concentration by adding the mean change score to the baseline value and used the SD of the baseline value under the assumption that it would be equal to the SD of the final value. If an article did not report the final value or change in the placebo group (21, 22) , we used the mean baseline vitamin B-12 status concentration and SD for the placebo group under the assumption that it would be equal to the final mean and SD. If dietary intake of vitamin B-12 (on top of the intervention) was not reported, we imputed 5.02 mg/d because this was the mean dietary intake of RCTs (n = 6) that reported dietary vitamin B-12 intake.
Data synthesis for observational studies
If a study reported the results separately for supplement users and nonsupplement users (23), we used only the group of non-VITAMIN B-12 INTAKE ASSOCIATED WITH BIOMARKERS supplement users in the analysis. If a study reported the results separately for a young subgroup and an older subgroup and separately for men and women (24) , we treated the study as 4 independent estimates in the analysis.
Risk of bias in individual studies
To ascertain the validity of included RCTs, we determined the adequacy of random assignment, concealment of allocation, and blinding of participants, personnel, and outcome assessors. We FIGURE 1. Results of the search strategy and study selection process for the meta-analyses on vitamin B-12 intake and vitamin B-12-related biomarkers in adults and elderly people. *We selected 28 RCTs for the overall meta-analysis, but because one article reported on 2 separate placebo-controlled trials (11), 4 studies included 2 vitamin B-12-treated groups (12) (13) (14) (15) , 2 studies reported only on men and women separately (15, 17) , and one study included 2 vitamin B-12-treated groups and 2 control groups (16), we eventually ended up with 37 estimates from RCTs in the overall meta-analysis. **We selected 21 observational studies for the overall meta-analysis, but because 4 articles did not report the association between vitamin B-12 intake and serum or plasma vitamin B-12 (27) (28) (29) (30) , one article did not report the mean dietary intake of vitamin B-12 (31) , and one article reported results separately for a young subgroup and an older subgroup and stratified by sex, we eventually included 19 estimates from observational studies in the overall meta-analysis. holoTC, holotranscobalamin; I-S-H, intake, status, and health; MMA, methylmalonic acid; RCT, randomized controlled trial; vit B12, vitamin B-12. hypothesized that the effect size might have differed according to the methodologic quality of studies.
To explore the variability in study results (heterogeneity), we performed a stratified meta-analysis with one subgroup by combining the evidence from RCTs and the other subgroup by combining the evidence from observational studies. In addition, since the association between vitamin B-12 intake and vitamin B-12-related biomarkers may be less strong in elderly people because of food-bound malabsorption of vitamin B-12, we investigated whether the mean age of the study population was a modifier of the association. Therefore, we performed a metaanalysis in subgroups for studies performed in adults (mean age of study population: .18 and #64 y) and for studies performed in elderly people (mean age of study population: .65 y). In addition, we investigated whether the dose of vitamin B-12 (categories: 0-3, 4-7, 8-10, 11-50, 51-249, and $250 mg/d), duration of trials (in wk), and matrix of provided vitamin B-12 (diet, enriched food product, or supplement) were variables that modified the association. We were not able to perform a stratified meta-analysis for sex because most studies included both men and women, and data were not available at the individual level.
Statistical analyses
The transformations used to derive coherent single-study estimates from available summary statistics per study have been described elsewhere (25) . In short, we estimated an intake-status regression coefficient À b Á for each individual study on the basis if of the assumption of a linear relation on the log e -log e scale (ln of intake compared with ln of status). Algebraically derivation of an estimate from each study of the regression coefficient
] enabled us to compare results from studies with heterogeneously reported associations and effects.
We calculated the overall pooled b and SE À b Á by using a random-effects meta-analysis, which estimated the betweenstudy variance by using the method of DerSimonian and Laird (26) and used this estimate to modify the weights used to calculate the summary estimate. The residual heterogeneity between studies was evaluated by using the I 2 statistic. Prespecified potential factors that could modify the association were explored by using stratified random-effects meta-analyses. We assessed the possibility of small study effects by evaluating a funnel plot that expressed the b by the inverse of its SE. The symmetry of this funnel plot was assessed both visually and formally by using Egger's test. Equation intercepts were estimated by using the mX (the mean of the vitamin B-12 intake on the ln scale) and the mY (mean of the vitamin B-12 status on the ln scale) for every observational study and weighted these by multiplying with the weighing factor of the study. Subsequently, we took the mean of the weighted mX and mean of the weighted mY as the coordination point at which the regression lines were hung up. This coordination point, together with bs, provided the intercept.
The statistical transformations to obtain bs and SE À b Á s were performed by using the program GenStat (version 13-SP2;VSN International Ltd), and the meta-analysis was performed with STATA software (version 11.0; StataCorp LP), with statistical significance defined as P , 0.05.
RESULTS
We identified 28 RCTs on vitamin B-12 intake and serum or plasma vitamin B-12 status that were eligible for our metaanalysis. Because one article reported on 2 separate placebocontrolled trials (11), 4 studies included 2 vitamin B-12-treated groups (12-15), 2 studies reported only on men and women separately (15, 17) , and one study included 2 vitamin B-12-treated groups and 2 control groups (16), we eventually included 37 estimates from RCTs in the analysis. These 37 estimates of RCTs of vitamin B-12 intake and serum or plasma vitamin B-12 status included, in total, 3398 subjects, and sample sizes ranged from 21 to 217 subjects ( Table 1) . The median duration of trials was 12 wk (range: 4-104 wk). Twenty-four trials used vitamin B-12 or multivitamin capsules, and 13 trials provided vitamin B-12 in a diet or enriched food product. The intervention dose ranged from 2.1 to 1000 mg/d.
We identified 21 observational studies of vitamin B-12 intake and serum or plasma vitamin B-12 status that were eligible for our meta-analyses. However, 4 articles did not report the association between vitamin B-12 intake and serum or plasma vitamin B-12 (27) (28) (29) (30) , and one article did not report the mean dietary intake of vitamin B-12 (31) . The obtainment of these data through author requests was unsuccessful. One article reported results separately for a young subgroup and an older subgroup and stratified by sex. We eventually included 19 estimates from observational studies in the analysis. The 19 estimates from observational studies included, in total, 12,570 subjects, and sample sizes ranged from 64 to 2156 subjects ( Table 2) . Two of the identified observational studies were originally nested case-control studies, and one study was originally a prospective cohort study; however, the associations between vitamin B-12 intake and serum or plasma vitamin B-12 status were analyzed cross-sectionally at baseline for all studies.
The combination of the 37 RCTs and 19 observational studies in one meta-analysis yielded an overall pooled b coefficient of 0.15 (95% CI: 0.13, 0.17; I 2 = 91%) ( Figures 2 and 3) . Because we applied a base-e logarithmic transformation on the vitamin B-12 intake and serum or plasma vitamin B-12 concentration before calculation of study-specific bs, the overall b represents the difference in the log e -transformed predicted value of serum or plasma vitamin B-12 status for each one-unit difference in the log e -tansformed value in vitamin B-12 intake. Therefore, an overall b of 0.15 meant that, for every doubling in vitamin B-12 intake, the vitamin B-12 serum or plasma concentration increased 2 b -fold (= 2 0.15 = 1.11), which corresponded to 11% (95% CI: 9.4%, 12.5%). This calculation meant that a person with an intake of 2 mg vitamin B-12/d would have a vitamin B-12 serum or plasma concentration that was 11% higher than that of a person with an intake of 1 mg vitamin B-12/d, or a person who had an intake of 8 mg vitamin B-12/d would have a vitamin B-12 serum or plasma concentration that was 11% higher than that of a person who had an intake of 4 mg vitamin B-12/d.
A stratified meta-analysis yielded an overall b of 0.17 (95% CI: 0.15, 0.20; I 2 = 88%) on the basis of RCTs only (n = 37) and an overall b of 0.10 (95% CI: 0.06, 0.14; I 2 = 94%) on the basis of observational studies only (n = 19) (Table 3 and Figure 3 ). We hypothesized that the larger b for RCTs may be explained by the lower baseline concentrations of serum or plasma vitamin B-12 in RCTs (mean 6 SD: 260 6 65 pmol/L) compared with in observational studies (320 684 pmol/L). A meta-analysis of VITAMIN B-12 INTAKE ASSOCIATED WITH BIOMARKERS 29 studies performed in adults (mean age of study population .18 and #64 y) yielded an overall b of 0.12 (95% CI: 0.08, 0.15; I 2 = 90%), whereas a meta-analysis in 27 studies performed in elderly (mean age of study population .65 y) yielded an overall b of 0.18 (95% CI: 0.15, 0.20; I 2 = 91%) ( Table 3) . We hypothesized that the larger b for the studies in elderly populations may be explained by the lower baseline concentrations of serum or plasma vitamin B-12 in elderly populations (243 6 54 pmol/L) than in adults populations (273 6 72 pmol/L). However, we took serum or plasma vitamin B-12 concentrations in placebo groups of RCTs as a proxy of baseline serum or plasma vitamin B-12 concentrations because mean baseline serum or plasma vitamin B-12 concentrations were infrequently reported in the original articles.
There was statistical evidence for substantial between-study heterogeneity in the overall meta-analysis as well as in the stratified meta-analyses for study design and mean age of the study population (adults compared with elderly persons). The stratification of the analysis for the dose of vitamin B-12 (categories: 0-3, 4-7, 8-10, 11-50, 51-249, and $250 mg/d), duration of the study (0-12 compared with $13 wk), and matrix of provided vitamin B-12 (diet, enriched food products, or capsules) did not explain the between-study heterogeneity. An evaluation of each of these potential sources of heterogeneity continuously and simultaneously in a meta-regression model revealed that the study design, mean age, and dose of vitamin B-12 provided, but not FIGURE 2. Random-effects meta-analysis of 19 Obs studies and 37 RCTs that evaluated the association or effect of dietary vitamin B-12 on serum or plasma vitamin B-12. bs represent regression coefficients for the linear association between log e -transformed vitamin B-12 intake and log e -transformed serum or plasma vitamin B-12 status. Black diamonds are point estimates for each study, horizontal lines are 95% CIs, open diamonds are summary estimates with the lateral tips of the open diamond indicating the 95% CI for the summary estimates. caps, capsules; enr., enriched; exerc, exercise; multivit caps, multivitamin capsules; Obs, observational; RCT, randomized controlled trial; vitB12 caps, vitamin B-12 capsules.
the study duration or matrix of vitamin B-12 provided, were significant determinants of the overall b with point estimates in the expected direction.
With regard to risk of bias, we assessed whether included trials were at low, unclear, or high risk of bias with regard to the random-sequence generation, allocation-sequence concealment, and blinding of participants, personnel, and outcome assessors.
Twenty-four RCTs were judged at low risk of bias, and 4 RCTs were judged at unclear risk of bias, with regard to the randomsequence generation. Twenty-two RCTs were judged at low risk of bias, and 6 RCTs were judged at unclear risk of bias, with regard to the blinding of participant, personnel,and outcome assessors. A subgroup analysis of RCTs with low risk of bias with regard to random-sequence generation and blinding did not substantially alter the overall pooled b, and thus, we decided not to exclude studies with an unclear risk of bias. The original research articles often did not describe whether the random assignment that was applied sufficiently concealed the allocation sequence to prevent foreseeing the allocation in advance or during enrollment. Therefore, 21 of 28 RCTs were judged at an unclear risk of bias with regard to the allocation-sequence concealment, and we decided not to perform a subgroup analyses with regard to this risk of bias. However, if there would have been bias with regard to the allocation concealment in these articles, this would have been generally associated with raised risk of overall bias. Visual inspection of the funnel plot indicated no evidence for small study effects, which was confirmed by a non-significant Egger's test.
We identified 6 RCTs on vitamin B-12 intake and serum or plasma MMA status that were eligible for a meta-analysis. Since one article reported on 2 separate placebo-controlled trials (11), one study included 2 vitamin B-12 groups and 2 control groups (16), and one study included 2 vitamin B-12-treated groups (12), we eventually were able to include 9 estimates from RCTs in the analysis ( Table 4 We identified 2 RCTs on vitamin B-12 intake and serum or plasma holotranscobalamin. One of these trials included 2 vitamin B-12-treated groups, which resulted in 3 estimates that were available from RCTs on serum or plasma holotranscobalamin ( Table 5) . These 3 estimates each showed that vitamin B-12 supplementation either through capsules (12) or enriched food products (32) significantly increased concentrations of holotranscobalamin TABLE 3 Pooled bs derived from random-effects meta-analyses of RCTs, observational studies, or both, and subgrouped according to mean age in the study population, representing regression coefficients for the linear association between log etransformed vitamin B-12 intake and log e -transformed serum or plasma vitamin B-12 status 1 RCTs, randomized controlled trials.
2 Meta-analysis of studies with a mean age of study population .18 and #64 y. 3 Meta-analysis of studies with a mean age of study population .65 y.
TABLE 4
RCTs (n = 9) that reported the effect of dietary vitamin B-12 intake on MMA status in apparently healthy adults or elderly persons in serum or plasma, but the number of RCTs was too small, and the heterogeneity in study characteristics was too large, to justify a meta-analysis.
DISCUSSION
This meta-analysis of RCTs and observational studies provided us with an estimate of the dose-response relation between vitamin B-12 intake and serum or plasma vitamin B-12 concentrations of log e ðyÞ ¼ 0:15 3 log e ðxÞ þ 5:31 ð2Þ
This estimate meant that the doubling of vitamin B-12 intake increased the vitamin B-12 concentration in serum or plasma by 11% (95% CI: 9.4%, 12.5%). This association was stronger in the meta-analysis of RCTs than in observational studies, and it was stronger in the meta-analysis of studies in elderly populations than in adult populations. We hypothesized that the larger pooled regression coefficient for studies in elderly populations may be explained by low baseline concentrations of serum or plasma vitamin B-12 in these populations. A meta-analysis of RCTs on MMA provided an overall b of 20.11, which meant that the doubling of vitamin B-12 intake decreased the MMA concentration in serum or plasma by 7%. These statements were based on studies with participants without severe deficiencies and, therefore, were valid when vitamin B-12 intake was $1.3 mg/d (mean vitamin B-12 intake in observational studies minus 2 SDs).
To conduct our meta-analysis, we had to make some assumptions related to the availability of required data or statistical issues. First, we assumed that, in RCTs that adjusted for baseline differences in serum or plasma values of vitamin B-12 between intervention and placebo groups by providing a change from baseline, values of vitamin B-12 biomarkers at the end of the intervention period could be estimated by adding this mean change to the baseline value. Thus, when postsupplementation concentrations of the vitamin B-12 biomarker were only reported as the change from baseline, we added this mean change to the baseline value. We used the SD of the baseline value in this case, under the assumption that it would be equal to the SD of the final value. Because SDs of change values tend to be less than the SDs of final values, the use of the SD of change values would have incorrectly increased the precision of estimates and their weights in the meta-analysis. Because only 6 of 37 estimates from RCTs reported the change from baseline as opposed to final values, we did not expect this to have major effects on the interpretation of the overall pooled effect. Second, if RCTs did not report the dietary intake of vitamin B-12 on top of the intervention, we imputed 5.02 mg/d because this value was the mean dietary intake of RCTs that did report dietary vitamin B-12 intake. The imputation of this value for unknown dietary intake inevitable introduced some amount of bias to calculated regression coefficients, with a stronger effect on the bs of RCTs with a low dose than of RCTs that provide a high dose of supplementation. We did not know the direction of the bias because we did not know the true intake, but because we had to impute this information for the majority of estimates, we expected that a bias in the estimates from one study would eventually cancel out against another study. However, because all participants were likely to consume some amount of vitamin B-12 in their diet, and we did not know this true intake, the imputation of mean dietary intakes of RCTs that did report intake was the most sensible choice.
Third, we assumed the independence of estimates when 2 intervention groups were compared with the same control group, which occurred in 4 RCTs. For each specific study, this assumption may have introduced a bias because a lower value for the control group would have increased both estimates of the intervention effect. Similarly, higher values for the control group would have decreased both estimates of the intervention effect. Another option to deal with this dependence would have been to omit one of the treatment groups entirely from the meta-analysis, with the consequence that not all available data from a study would have been used. Our simple approach used all data but added relatively more weight to the control group in the overall meta-analysis. In our analyses, 4 RCTs included 2 vitamin B-12-treated groups and one common control group, which meant that 8 of 37 estimates from RCTs of the overall meta-analyses may have been slightly biased. However, because intervention and control groups originated randomly from the same source population, a bias in estimates from one study could have eventually cancelled out against similar studies when their number increased. Therefore, we did not expect this to have major effects on the interpretation of the overall pooled effect.
Fourth, the meta-analysis required transformations of intake and biomarker data to a common scale because the studies included in our meta-analyses had different ways of reporting the relation between vitamin B-12 intake and biomarkers of vitamin B-12 status in blood. These differences between studies were a nuisance when we attempted to quantitatively summarize the data by using conventional meta-analytic methods. We standardized the different ways of reporting by transforming both intake and biomarker data to the double log e scale, which allowed use to derive a standardized estimate from each study of the regression coefficient and its SE as a basis for comparison of these heterogeneously reported results. A simulation study was conducted to validate the performance of the transformation that we used, and the study clearly showed that there was no observable bias associated with the transformations (25) . Finally, we assumed a linear relation on the double log e scale. This rigorous but flexible transformation allowed us to pool bs and report these as a dose-response relation between vitamin B-12 intake and serum or plasma vitamin B-12 concentrations or MMA. Compared with a conventional meta-analysis of mean differences between high-and low-exposed subjects, a linear relation on the double log e scale with a slope ,1 allowed use to model biomarker levels as a non-linear but monotonic concave function of dose, which is considered a more likely shape in biology. Moreover, because this transformation could be applied to both RCT and observational data, this standardization and modeling also allowed us to compare RCTs and observational studies on vitamin B-12 intake and biomarkers of vitamin B-12 status.
In our stratified analyses, we observed steeper slopes in RCTs than in observational studies and in elderly than in adults. For the meta-analysis stratified by study design (RCT compared with observational), these results were anticipated because the intakestatus regression coefficient for observational studies was likely to be attenuated by random and intake-related errors in the assessment of dietary vitamin B-12 intake (33). In RCTs, regression dilution plays no considerable role because the dose can be considered fixed at each level of dosage, and random errors are completely in the assessment of biomarkers. When both study types were combined in one analysis, RCTs appeared to drive the overall estimate, probably because of the large dose range they represented. Thus, the overall observed association was likely to be weakened, possible more so in observational studies. In contrast, the combination of these 2 types of studies in one metaanalysis might have partially cancelled out differences because of the measurement error in observational studies that would lead to an overall estimate of the dose-response relation that might have served as a practical approach to evaluate the relation between population vitamin B-12 intake and population vitamin B-12 status.
All studies included in the meta-analyses had different study designs, different follow-up times, different doses or forms of dietary vitamin B-12 intake, different analytic methods to assess vitamin B-12 in blood, and differences in populations studied. Therefore, we were not surprised that, when these studies were combined in a meta-analysis, a large heterogeneity was observed between studies. This between-study heterogeneity may have been caused by methodologic factors, such as measurement methods to assess the dietary intake of vitamin B-12 and assess serum or plasma vitamin B-12 concentrations, or by biological factors, such as differences in study population characteristics (age and sex), differences in doses of provided vitamin B-12 (amount, one or more doses per day, and study duration). We have considered the mean age of the study population, study design, percentage of women in the study, duration of trials and dose and form of vitamin B-12 provided; however, these factors did not significantly explain the between-study heterogeneity. To come to a thorough explanation of the between-study heterogeneity in this meta-analysis, we would have needed an individual participant data meta-analysis in which the raw individual participant data were provided by the original study investigators and reanalyzed centrally and combined in a pooled analysis. Then, stratified analyses could have been based on participant characteristics instead of study characteristics, and the statistical analysis would have been more powerful. However, an individual participant data meta-analysis is a major undertaking in terms of time, costs, and collaboration, and an inability to include individual participant data from all relevant studies may have introduced a selection bias. Moreover, our meta-analytic approach to combine evidence from RCTs and observational studies was by no means an attempt to accurately describe the biological relation between actual vitamin B-12 intake and vitamin B-12 concentrations in blood under strict experimental conditions and on an individual level but, rather, to simulate a dose-response relation between vitamin B-12 intake and status that would be useful for surveillance studies with a public health point of view and, as such, deliberately incorporated differences between dietary assessment methods, laboratory assessment methods, and participant characteristics to ensure a broad external validity. Thus, the heterogeneity reflected a lack of standardization of methods and the true heterogeneity between study populations and necessarily enters uncertainty into the application of such data for public health purposes.
The meta-analyses was conducted within the context of the European Micronutrient Recommendations Aligned project as a means to provide additional evidence for the underpinning of reference values for the vitamin B-12 intake of populations. Whether the dose-response relation as provided in this article could be used as either qualitative or quantitative evidence to substantiate the daily vitamin B-12 intake dose necessary to achieve normal or optimal amounts of biomarkers for vitamin B-12 status remains a matter of discussion regarding the cutoff for biomarkers of vitamin B-12 and the predictive value of vitamin B-12 concentration for relevant functional health outcomes such as osteoporosis, cognition, and anemia.
In conclusion, our meta-analyses provided us with an estimate of the dose-response relation between vitamin B-12 intake and biomarkers of vitamin B-12. On the basis of 56 estimates in 15,968 subjects, the results indicated that a doubling of vitamin B-12 increases serum or plasma levels by 11% (95% CI: 9.4%, 12.5%) and slightly more in elderly persons and RCTs. For MMA, 9 studies (797 subjects) were available, which led to an estimate of a 7% decrease in biomarker values (95% CI: 210%, 24%) for a doubling in intake. No pooled estimate could be obtained for holotranscobalamin. Because vitamin B-12 concentrations are considered intermediates in the causal path to health benefits, and the heterogeneity between study results reflected real uncertainty in the evidence base, these issues must be taken into account when our dose-response data are used as complementary evidence for the underpinning of vitamin B-12 reference values.
The original conception of the systematic review was undertaken by the European Micronutrient Recommendations Aligned Network and coordinated by partners who are based at Wageningen University and the University of East Anglia.
